Savara (SVRA) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
24 Apr, 2026Executive summary
Annual meeting scheduled for June 4, 2026, with virtual participation available to shareholders.
Shareholders are invited to vote on key proposals, including director elections, amendments to the certificate of incorporation, incentive plan changes, auditor ratification, and executive compensation.
Voting matters and shareholder proposals
Election of six directors to serve until the next annual meeting, with all nominees recommended by the board.
Proposal to amend the certificate of incorporation to increase authorized common stock from 300,000,000 to 600,000,000.
Proposal to amend the 2024 Omnibus Incentive Plan, increasing shares authorized for issuance by 18,900,000.
Ratification of RSM US LLP as independent registered public accounting firm for fiscal year ending December 31, 2026.
Advisory vote on executive compensation (say-on-pay) included.
Board of directors and corporate governance
Six director nominees listed: Matthew Pauls, Nevan Elam, Richard J. Hawkins, Joseph S. McCracken, David A. Ramsay, and An van Es-Johansson.
All nominees are recommended for election by the board.
Latest events from Savara
- MOLBREEVI showed strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation17 Jul 2026 - MOLBREEVI advances toward approval with strong data, new diagnostics, and robust launch plans.SVRA
Leerink’s Global Healthcare Conference 20258 Jul 2026 - Molbreevi's positive phase 3 data positions it for US approval and broad APAP market impact.SVRA
Oppenheimer 35th Annual Healthcare Life Sciences Conference 20258 Jul 2026 - All proposals, including director elections and plan amendments, were approved.SVRA
AGM 20264 Jun 2026 - MOLBREEVI targets a 5,500-patient US market with strong launch readiness and high approval confidence.SVRA
Jefferies Global Healthcare Conference 20263 Jun 2026 - MOLBREEVI nears approval for aPAP, backed by strong data and robust launch preparations.SVRA
H.C. Wainwright 4th Annual BioConnect Investor Conference22 May 2026 - Q1 2026 net loss rose to $37.3M as regulatory filings advanced and cash reserves remained strong.SVRA
Q1 202613 May 2026 - MOLBREEVI demonstrated strong efficacy and safety in autoimmune PAP, targeting a $2B+ U.S. market.SVRA
Corporate presentation12 May 2026 - Shareholders to vote on board elections, share increase, incentive plan, and executive pay.SVRA
Proxy filing24 Apr 2026